BASi Elects New Director
Complete the form below to unlock access to ALL audio articles.
"We are pleased to welcome Mr. Hamot to the Board and look forward to working with him," Chairman John Landis said. The Board of Directors also appointed Mr. Hamot to the Nominating Committee.
Mr. Hamot is the managing member of Roark Rearden & Hamot Capital Management, an investment firm that manages the Costa Brava Partnership III LP investment fund, which generally focuses on companies neglected by research analysts and the press with enterprise values ranging from $100 million to $1 billion. Mr. Hamot also has extensive experience serving as a director. Mr. Hamot currently serves as the Chairman of the Board of Orange 21, Inc., a designer and distributor of premium sunglasses and goggles sold internationally, and Irvine Sensors Corporation, a corporation engaged in the design, development, manufacture and sale of cutting-edge internet security systems and 3D stacked microchips for defense, security and commercial applications. Mr. Hamot also previously served as Chairman of the Board of Bradley Pharmaceuticals, a specialty pharmaceutical company with products focused on the dermatology and gastroenterology markets. Mr. Hamot holds a B.A. in Economics from Princeton University.
